Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone44-0-12-3544-2780
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$59.75 million
Profitability
Miscellaneous
Employees215
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its earnings results on Tuesday, August, 6th. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.07. The firm had revenue of $19.60 million for the quarter, compared to the consensus estimate of $19.32 million. Oxford Immunotec Global had a net margin of 208.48% and a return on equity of 14.76%. The business's quarterly revenue was up 17.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.25) EPS. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What guidance has Oxford Immunotec Global issued on next quarter's earnings?
Oxford Immunotec Global updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $71-73 million, compared to the consensus revenue estimate of $70.57 million.
What is the consensus analysts' recommendation for Oxford Immunotec Global?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.
Has Oxford Immunotec Global been receiving favorable news coverage?
News coverage about OXFD stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford Immunotec Global earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Oxford Immunotec Global.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Heska (HSKA), Meridian Bioscience (VIVO), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), GeneNews (GNWSF), Achieve Life Sciences (ACHV) and Arca Biopharma (ABIO).
What other stocks do shareholders of Oxford Immunotec Global own?
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
- Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
- Ms. Karen C. Koski, VP of Strategy & Investor Relations
Who are Oxford Immunotec Global's major shareholders?
Oxford Immunotec Global's stock is owned by many different of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (11.70%), Invesco Ltd. (10.00%), Grandeur Peak Global Advisors LLC (2.97%), Renaissance Technologies LLC (2.07%), Morgan Stanley (1.89%) and Senvest Management LLC (1.83%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.
Which major investors are selling Oxford Immunotec Global stock?
OXFD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Cortina Asset Management LLC, Russell Investments Group Ltd., Northern Trust Corp, Granite Investment Partners LLC, Essex Investment Management Co. LLC, D. E. Shaw & Co. Inc. and Invesco Ltd.. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.
Which major investors are buying Oxford Immunotec Global stock?
OXFD stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Morgan Stanley, Grandeur Peak Global Advisors LLC, Senvest Management LLC, Paloma Partners Management Co and Stonepine Capital Management LLC. View Insider Buying and Selling for Oxford Immunotec Global.
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $13.78.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $369.72 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.
What is Oxford Immunotec Global's official website?
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
